Cover Image
市場調查報告書

搭配診斷 (CDx)的主要開發企業、廠商、銷售企業的分析與簡介 (2016年)

Medical Device Leader Series - Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016: Market Analysis & Company Profiles - Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson

出版商 Visiongain Ltd 商品編碼 372573
出版日期 內容資訊 英文 167 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
搭配診斷 (CDx)的主要開發企業、廠商、銷售企業的分析與簡介 (2016年) Medical Device Leader Series - Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016: Market Analysis & Company Profiles - Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson
出版日期: 2016年08月22日 內容資訊: 英文 167 Pages
簡介

全球搭配診斷實驗上收益,預計2020年達到105億2,000萬美元。銷售額預計到2026會更加上升,顯示強勁收益成長。

本報告提供全球搭配診斷 (CDx) 市場上主要企業17家公司 (開發企業、廠商、銷售企業)的產品,技術,聯盟,R&D及業績等相關評價,收益預測,競爭機會,採訪,及定性分析的資訊彙整,為您概述為以下內容。

第1章 報告概要

第2章 搭配診斷的簡介

  • 治療範例的變化
  • 個體化醫療是什麼?
  • 體外診斷 (IVD) 及標靶治療:個體化醫療核心
  • 搭配診斷:個體化醫療的工具
  • 搭配診斷的生物標記
  • 搭配診斷的開發
  • 搭配診斷市場上法規

第3章 全球搭配診斷市場

  • 全球搭配診斷市場
  • 全球搭配診斷市場上銷售額預測
  • 搭配診斷:IVD市場市場佔有率擴大
  • 搭配診斷市場:各次級市場
  • 治療診斷:CDx市場急速成長市場區隔
  • 主要的搭配診斷次級市場的市場佔有率的變化
  • 促進要素
  • 抑制因素

第4章 主要美國據點的搭配診斷企業

  • Abbott Laboratories, Inc.
  • Myriad Genetics
  • Genomic Health
  • Thermo Fisher Scientific - Life Technologies
  • Johnson & Johnson
  • Laboratory Corporation of America (LabCorp)
  • Illumina

第5章 歐洲的主要搭配診斷企業

  • Roche
  • Qiagen
  • Agilent Technologies (Dako)
  • bioMerieux
  • Siemens Healthcare
  • MDxHealth

第6章 其他主要搭配診斷企業

  • MedGenome
  • Diagnocure
  • Seegene Inc.
  • Savyon Diagnostics
  • 其他主要搭配診斷聯盟

第7章 調查採訪

第8章 搭配診斷市場定性分析

  • SWOT分析
  • STEP分析

第9章 結論

圖表清單

目錄
Product Code: PHA0138

Title:
MEDICAL DEVICE LEADER SERIES: TOP COMPANION DIAGNOSTICS (CDX) DEVELOPERS, MANUFACTURERS AND MARKETERS IN 2016
Market Analysis and Company Profiles Including Abbott Laboratories, Myriad Genetics, Roche, Qiagen, Agilent Technologies, Siemens, Johnson & Johnson and Other Companies in the US, Europe, Israel, India, Canada and South Korea, Exploring those Diagnostic Products for Personalised Medicine and Partnerships with Pharmaceutical Developers.

Companion Diagnostics - Discover Leading Companies' Activities and Outlooks

How are companies in the companion diagnostics (CDx) industry performing? Visiongain's new report gives you data, analysis and discussions for producers of those medical devices.

Our study lets you assess top companies in that industry and market, showing you their activities and outlooks. There you see financial results, opinion, trends, opportunities and revenue prediction for those developments in biomarkers, genomics, targeted therapies, theranostics and personalised medicine.

That way you explore the potentials of established and rising companies. Please read on to scan those 17 leading competitors and see what their future market could be worth.

Forecasts and discussions to help you stay ahead in knowledge and authority

Our new study assesses 17 leading companies and analyses that overall market. There you find sales results, revenue forecasting and growth rates. In our 166 page report you get 34 tables, 23 charts and an interview with MedGenome.

You also gain qualitative analyses, including discussion of research and development. Our work lets you assess the most beneficial and lucrative applications of those diagnostic tests for advancing human medicine, making it more personalised. Discover what is happening.

Company profiles - see why firms succeed, also exploring their potentials

Our report profiles 17 leading companies worldwide. Our investigation discusses prominent companies, exploring their activities by:

  • Analysing companion diagnostic product portfolios and technologies
  • Investigating the status of commercial developments
  • Assessing R&D and applications for those medical devices
  • Uncovering organisations' strengths, weaknesses, activities, strategies and prospects
  • Giving qualitative analyses and revenue forecasting of the overall world companion diagnostics market from 2016 to 2026.

Our survey shows you how technology changes, as well as explaining how diagnostic needs develop from 2016. Assess the rising demand for companion diagnostic products.

Prospects for US-based developers, manufacturers and marketers

Chapter 4 profiles companion diagnostic manufacturers based in the United States. Leading companies profiled there are these seven organisations:

  • Abbott Laboratories
  • Myriad Genetics
  • Genomic Health
  • Thermo Fisher Scientific
  • Johnson & Johnson
  • LabCorp
  • Illumina.

There you discover what the future holds, seeing how companies compare and compete. Suppliers and users of companion diagnostic systems will benefit from 2016.

Outlooks for European manufacturers of those diagnostic medical devices

Chapter 5 profiles companion diagnostic manufacturers based in Europe. Leading companies profiled there are these six firms:

  • Roche
  • Qiagen
  • Agilent Technologies
  • bioMérieux
  • Siemens
  • MDxHealth.

Many opportunities remain, with expanding revenues likely from 2016 to 2026. Discover what is possible, seeing how you could gain.

Potentials of developers and producers in the rest of the world

Chapter 6 profiles companion diagnostic manufacturers based in the rest of the world. Leading companies profiled there are these four organisations:

  • MedGenome
  • Diagnocure
  • Seegene
  • Savyon Diagnostics.

Our work shows you possibilities for improving those technologies and raising sales, harnessing biopharmaceuticals, gene technologies and targeted therapies, including personalised medicine. See what the present and future hold, finding how you could gain.

Forces affecting the companion diagnostics industry - what shapes its present and future?

Our report discusses pressures, opportunities and other events affecting that industry and market from 2016, including these influences:

  • Biomarker discovery and technologies including genomics, pharmacogenomics, proteomics and metabolomics
  • Laboratory developed tests (LDT)
  • Theranostics - the fastest growing segment of the CDx market
  • Partnerships and other deals, including M&A and collaborations with pharma companies including Eli Lilly, AstraZeneca, Merck, GSK, Pfizer and Novartis
  • Applications in cancer therapy and other therapeutic fields
  • Regulations for companion diagnostic tests - opportunities and challenges.

With our analysis you assess that industry's strengths, weaknesses, opportunities and threats. See what is happening and how to gain. That way you explore what restricts and stimulates companies developing, producing, marketing and selling those diagnostic tools.

Value of that market in 2020 - what sales growth is possible?

Our investigation predicts overall world revenues for companion diagnostic tests will reach $10.52bn in 2020. Those sales will rise further to 2026, showing strong revenue growth. Many opportunities exist for companies large and small as personalised medicine expands.

Ways Medical Device Leader Series: Top Companion Diagnostics (CDx) Developers, Manufacturers and Marketers in 2016 helps your work

In particular our new study gives you this knowledge to benefit your research, analyses, plans and presentations:

  • Profiles of 17 leading companion diagnostic companies - assess their products, technologies, partnerships, R&D and results
  • Forecasted revenue to 2026 for that overall market at world level - discover expected sales rises for companion diagnostic products, finding the gains possible
  • Competition and opportunities - explore what affects that industry, assessing forces influencing its sales and determining its future
  • Opinion from an interview with a leading company - gain information to help you stay ahead in knowledge, benefiting your reputation for commercial insight.

That new study, by our in-house analysts in the UK, has the purpose of helping your work. There you gain data and discussions you find nowhere else, helping you succeed.

Independent analysis to benefit your authority on companion diagnosticsc

Our work gives independent analysis. There you receive competitive intelligence found only in that report, seeing where technological and financial prospects are most promising.

With our study you are less likely to fall behind in knowledge or miss opportunity. See how you could help your research, analyses and decisions, also saving time and benefiting your authority. Explore that industry's future, seeing what is possible and how you could gain.

Our new investigation is for everyone analysing companion diagnostic tests and associated medical products. There you find data, trends, opportunities and forecasts. Avoid missing out. Instead benefit in knowledge and influence by getting our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of the Top Companion Diagnostic Companies
  • 1.2. Why You Should Read This Report
  • 1.3. How This Report Delivers
  • 1.4. Main Questions Answered by This Industry Survey
  • 1.5. Who is This Study For?
  • 1.6. Methods of Research and Analysis
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Associated Visiongain Reports
  • 1.9. About Visiongain

2. Introduction to Companion Diagnostics

  • 2.1. Changing Paradigms of Treatment
  • 2.2. What is Personalised Medicine?
  • 2.3. In Vitro Diagnostics (IVD) and Targeted Therapies: The Core of Personalised Medicine
    • 2.3.1. What are In Vitro Diagnostic (IVD) Tests?
    • 2.3.2. How IVDs Help Provide Personalised Treatment
  • 2.4. Companion Diagnostics: Tools for Personalised Medicine
    • 2.4.1. Theranostics: A Subset of Companion Diagnostics
  • 2.5. Biomarkers to Companion Diagnostics
    • 2.5.1. Advancements in Biomarker Discovery
    • 2.5.2. Genomics
    • 2.5.3. Pharmacogenomics
    • 2.5.4. Genomic Biomarkers in Oncology
    • 2.5.5. Proteomics
    • 2.5.6. Metabolomics
  • 2.6. Development of Companion Diagnostics
  • 2.7. Regulations in the Companion Diagnostics Market
    • 2.7.1. FDA's Draft Guidance on Companion Diagnostics
      • 2.7.1.1. Laboratory Developed Tests (LDT) - A New Direction

3. The World Companion Diagnostics Market, 2016-2026

  • 3.1. The Global Companion Diagnostics Market, 2015
  • 3.2. The Global Companion Diagnostics Market Sales Forecast, 2016-2026
  • 3.3. Companion Diagnostics: Increasing Market Share of the IVD Market
  • 3.4. The Companion Diagnostics Market by Submarket, 2015
  • 3.5. Theranostics: Fastest Growing Segment of the CDx Market
  • 3.6. Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2016-2026
  • 3.7. Drivers
    • 3.7.1. Stakeholders in the Companion Diagnostics Market
    • 3.7.2. Regulatory Authorities
    • 3.7.3. Payers
    • 3.7.4. Partnerships
  • 3.8. Restraints
    • 3.8.1. Competitive Landscape
    • 3.8.2. Testing Laboratories
    • 3.8.3. Physicians and Patients

4. Leading US-Based Companion Diagnostic Companies, 2016

  • 4.1. Abbott Laboratories, Inc.
    • 4.1.1. Abbott Laboratories: Financial Overview
    • 4.1.2. Companion Diagnostics Product Portfolio
      • 4.1.2.1. Vysis ALK Break Apart FISH Probe Kit
      • 4.1.2.2. PathVysion HER-2KKKKK DNA Probe Kit
    • 4.1.3. Companion Diagnostics in Pipeline
    • 4.1.4. Recent Activity and Collaborations
      • 4.1.4.1. Collaboration with Merck
      • 4.1.4.2. Collaborative Efforts with Idera
      • 4.1.4.3. Collaboration with AstraZeneca
  • 4.2. Myriad Genetics
    • 4.2.1. Myriad Genetics: Financial Overview
    • 4.2.2. Myriad Genetics: Companion Diagnostics Product Portfolio
      • 4.2.2.1. myRisk Hereditary Cancer Test
      • 4.2.2.2. BRACAnalysis®
      • 4.2.2.3. CCP Assay
      • 4.2.2.4. PREZEON™
    • 4.2.3. Myriad Genetics: Companion Diagnostics Pipeline
      • 4.2.3.1. HRD Assay
    • 4.2.4. Myriad Genetics: Companion Diagnostics Collaborations:
      • 4.2.4.1. Myriad/AstraZeneca: Premarket Approval Application
      • 4.2.4.2. Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
      • 4.2.4.3. Myriad/ TESARO Companion Collaboration
      • 4.2.4.4. Collaboration with AbbVie
      • 4.2.4.5. Agilent/Bristol-Myers Squibb
  • 4.3. Genomic Health
    • 4.3.1. Genomic Health: Financial Overview
    • 4.3.2. Genomic Health: Companion Diagnostics Product Portfolio
      • 4.3.2.1. Oncotype Dx Portfolio
      • 4.3.2.2. Oncotype SEQ
    • 4.3.3. Genomic Health: Companion Diagnostics in Pipeline
      • 4.3.3.1. RxPonder Trial
    • 4.3.4. Genomic Health: Collaborations & Partnerships
      • 4.3.4.1. Partnership with OncoMed
      • 4.3.4.2. Genomic Health Partners with Epic Sciences
  • 4.4. Thermo Fisher Scientific - Life Technologies
    • 4.4.1. Thermo Fisher: Financial Overview
    • 4.4.2. Thermo Fisher: Geographic Segmentation
    • 4.4.3. Recent Collaborations and Acquisitions
      • 4.4.3.1. Acquisition of Life Technologies
      • 4.4.3.2. Acquisition of Prionics
      • 4.4.3.3. Acquisition of Advanced Scientifics, Inc.
      • 4.4.3.4. Acquisition of Alfa Aesar
      • 4.4.3.5. Affymetrix: Thermo Fisher's Next Target
      • 4.4.3.6. Thermo Fisher: Developing a ‘Universal' Companion Diagnostics Using Next Generation Sequencing
      • 4.4.3.7. Thermo Fisher: Life Technologies Collaborates with Merck Serono
      • 4.4.3.8. Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
  • 4.5. Johnson & Johnson
    • 4.5.1. Johnson & Johnson: Financial Overview
    • 4.5.2. Johnson & Johnson Division by Region
    • 4.5.3. Johnson & Johnson: Companion Diagnostics Portfolio
  • 4.5.3.1. Companion Diagnostics Center of Excellence
    • 4.5.4. Johnson & Johnson: Companion Diagnostics Partnerships
      • 4.5.4.1. Collaboration with Tianjin Medical University Cancer Institute and Hospital
      • 4.5.4.2. Partnership with Massachusetts General Hospital
      • 4.5.4.3. Partnership with Biocartis
  • 4.6. Laboratory Corporation of America (LabCorp)
    • 4.6.1. LabCorp: Financial Overview
    • 4.6.2. LabCorp Companion Diagnostics Portfolio
    • 4.6.3. Recent M&A Activity and Other Key Developments
      • 4.6.3.1. Agreement with Medco Health Sciences
      • 4.6.3.2. Non-Exclusive License Agreement with Merck
      • 4.6.3.3. Acquisition of Monogram Biosciences
      • 4.6.3.4. Acquisition of Genzyme Genetics
      • 4.6.3.5. Partnership with ARCA Biopharma
  • 4.7. Illumina
    • 4.7.1. Illumina: Financial Overview
    • 4.7.2. Illumina: Companion Diagnostics Product Portfolio
      • 4.7.2.1. MiSeqDx™ System
    • 4.7.3. Illumina: Recent Activity & Collaborations
      • 4.7.3.1. AstraZeneca Partners with Illumina
      • 4.7.3.2. bioMérieux Collaborates with Illumina

5. Leading European Companion Diagnostic Companies, 2016

  • 5.1. Roche: Global Diagnostics Leader
    • 5.1.1. Ventana Medical Systems (Roche)
    • 5.1.2. Roche: Financial Overview
    • 5.1.3. Roche Diagnostics Geographic Segmentation
    • 5.1.4. Roche's Collaborations and Recent Activity
    • 5.1.5. Roche Diagnostics: Companion Diagnostics Product Portfolio & Pipeline
    • 5.1.6. Ventana Companion Diagnostics: Robust New Prototype Assays
    • 5.1.7. Recent Companion Diagnostic External Collaborations
      • 5.1.7.1. Foundation Medicine and Roche Collaborate
      • 5.1.7.2. Ventana Partners with Genmab
      • 5.1.7.3. Ferring Collaborates with Roche for CDx Development for Infertility Treatment
      • 5.1.7.4. MedImmune Partners with Ventana
      • 5.1.7.5. Merck Enters Agreement with Ventana
      • 5.1.7.6. AstraZeneca and Roche Partnership
      • 5.1.7.7. Boehringer Ingelheim Collaborate with Roche
      • 5.1.7.8. ImmunoGen Enter Agreement with Ventana
    • 5.1.8. Roche Diagnostics: Major M&A Activity and Strategic Partnerships
      • 5.1.8.1. Genia Acquisition to Strengthen DNA Sequencing Capabilities
      • 5.1.8.2. IQuum Acquisition Allows Movement into POC MDx Market
      • 5.1.8.3. Seragon Acquisition Strengthens Leading Position in Oncology
      • 5.1.8.4. Santaris Acquisition Enhances Roche's Position in RNA-Targeted Drugs Market
      • 5.1.8.5. Bina Acquisition Brings Big Data Solution to Support NGS Development
      • 5.1.8.6. Dutalys Acquisition Enhances Roche's mAB Portfolio
      • 5.1.8.7. Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
      • 5.1.8.8. Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
      • 5.1.8.9. Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
      • 5.1.8.10. GENEWEAVE and Kapa Acquisitions Help Cement Roche's Position as the Market Leader
  • 5.2. Qiagen
    • 5.2.1. Qiagen: Financial Overview
    • 5.2.2. Qiagen: Geographic Segmentation
      • 5.2.2.1. Qiagen: Companion Diagnostics Collaborations
      • 5.2.2.2. Collaboration with Eli Lilly
      • 5.2.2.3. Collaboration with AstraZeneca
      • 5.2.2.4. Collaboration with Astellas Pharma
      • 5.2.2.5. Collaboration with Novartis
      • 5.2.2.6. Collaboration with Array BioPharma
      • 5.2.2.7. Collaboration with Protagen
  • 5.3. Agilent Technologies (Dako)
    • 5.3.1. Life Sciences and Diagnostics Business
    • 5.3.2. Agilent Life Sciences and Diagnostics: Financial Overview
    • 5.3.3. Agilent: Next Generation Sequencing Platforms
    • 5.3.4. Recent Companion Diagnostic Collaborations
      • 5.3.4.1. Merck and Aglient Cancer Collaborations
      • 5.3.4.2. Pfizer and Aglient an Ongoing Collaboration
      • 5.3.4.3. Bristol-Myers Squibb and Aglient Partnership
  • 5.4. bioMérieux
    • 5.4.1. bioMérieux: Financial Overview
    • 5.4.2. Sales by Region, 2014
    • 5.4.3. Sales by Technology, 2015
    • 5.4.4. Companion Diagnostics: Recent M&A Activity & Collaboration
      • 5.4.4.1. Collaboration with Gilead Sciences
      • 5.4.4.2. Collaboration with Ipsen
      • 5.4.4.3. Collaboration with Merck
      • 5.4.4.4. Collaborations with GSK and Novartis
      • 5.4.4.5. Mergers, Acquisitions and Collaborations
    • 5.4.5. bioTheranostics: Subsidiary for Oncology Diagnostics
  • 5.5. Siemens Healthcare
    • 5.5.1. Siemens: Financial Overview
    • 5.5.2. Siemens Healthcare
    • 5.5.3. Siemens Diagnostics
    • 5.5.4. Outperforming the Market
    • 5.5.5. Companion Diagnostics
      • 5.5.5.1. Partnership with Pfizer
      • 5.5.5.2. Partnership with ViiV Healthcare
      • 5.5.5.3. Partnership with Tocagen
  • 5.6. MDxHealth
    • 5.6.1. MDxHealth: Financial Overview
    • 5.6.2. Companion Diagnostics
      • 5.6.2.1. PharmacoMDx
      • 5.6.2.2. PredictMDx for Brain Cancer
      • 5.6.2.3. PredictMDx for Colon Cancer
    • 5.6.3. R&D Capabilities
    • 5.6.4. Recent Collaborations and Partnerships
      • 5.6.4.1. Cerba HealthCare Belgium Collaboration
      • 5.6.4.2. SouthGenetics Partnership
      • 5.6.4.3. Sumitomo Sign Pharmaco Partnership for Japan
      • 5.6.4.4. Partnership with GSK

6. Leading Rest of the World Companion Diagnostic Companies, 2016

  • 6.1. MedGenome
    • 6.1.1. MedGenome: Companion Diagnostics Product Portfolio
      • 6.1.1.1. Integrated Genomics Platform
      • 6.1.1.2. OncoPept
      • 6.1.1.3. OncoMD
      • 6.1.1.4. Next-Generation Sequencing Informatics
  • 6.2. Diagnocure
    • 6.2.1. Diagnocure Products
      • 6.2.1.1. Gene Expression and Copy Number Variation (CNV) Analysis
      • 6.2.1.2. Mutation Detection
      • 6.2.1.3. SNP Genotyping
      • 6.2.1.4. Platform and Laboratory Environment
    • 6.2.2. DiagnoCure Collaborations and Partnerships
  • 6.3. Seegene Inc.
    • 6.3.1. Seegene: Product Portfolio
      • 6.3.1.1. MuDT™(Multiple Detection Temperatures) Technology
      • 6.3.1.2. TOCE™ Technology
      • 6.3.1.3. DPO™ Technology
      • 6.3.1.4. READ Technology
      • 6.3.1.5. ACP™ Technology
    • 6.3.2. Seegene Collaborations and Partnerships
  • 6.4. Savyon Diagnostics
    • 6.4.1. Savyon: Product Portfolio
      • 6.4.1.1. NanoCHIP®
    • 6.4.2. Savyon Diagnostics Product Lines
    • 6.4.3. Savyon Diagnostics Services
  • 6.5. Other Leading Companion Diagnostics Partnerships

7. Research Interview

  • 7.1. Dr Ramprasad, Chief Operating Officer, and Mr Hiranjith G H, Director, Corporate Planning, MedGenome
    • 7.1.1. MedGenome Overview
    • 7.1.2. CDx Portfolio at MedGenome
    • 7.1.3. MedGenome's Competitive Advantage
    • 7.1.4. Future Directions For MedGenome and the Industry

8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026

  • 8.1. SWOT Analysis of the Companion Diagnostics Market, 2016-2026
    • 8.1.1. Strengths
      • 8.1.1.1. A CDx Strategy Decreases the Length of Approval Process
      • 8.1.1.2. Premium Prices for Companion Diagnostics
      • 8.1.1.3. A CDx Development Strategy Can Generate More Effective Drugs
      • 8.1.1.4. Therapeutics Tied with CDx can have Safer Profiles
      • 8.1.1.5. Reducing the Cost of Healthcare
      • 8.1.1.6. Increased Regulatory Scrutiny on Marketed Drugs
      • 8.1.1.7. Targeted Therapies Will Drive the CDx Market
    • 8.1.2. Weaknesses
      • 8.1.2.1. Reimbursement Challenges
      • 8.1.2.2. Lack of Clear Regulatory Guidelines
      • 8.1.2.3. Capital Intensity is High
    • 8.1.3. Opportunities
      • 8.1.3.1. Fast-growing Emerging Markets
      • 8.1.3.2. Next Generation Sequencing
      • 8.1.3.3. Many New CDx/ Pharma Company Partnerships
    • 8.1.4. Threats
      • 8.1.4.1. Complex Business Models and Business Partnerships
      • 8.1.4.2. Medical Device Excise Tax
  • 8.2. STEP Analysis of the Companion Diagnostics Market, 2016-2026
    • 8.2.1. Social Factor: Raising Awareness will Lead to Greater Product Adoption
    • 8.2.2. Technologically Innovation Driven - Growing Manufacturing Efficiency
    • 8.2.3. Economic Potential: Emerging Markets Create Demand
    • 8.2.4. Political Issues: Government Influence

9. Conclusions from Our Research and Analysis

  • 9.1. Overview
  • 9.2. Theranostics: A Fast Growing Market
  • 9.3. Leading Companion Diagnostic Companies
  • 9.4. Pharmaceutical/Diagnostic Partnership Model
  • 9.5. Oncology is the Leading Therapy Area Driving Companion Diagnostics
  • 9.6. Commercial Drivers of the Companion Diagnostics Market
  • 9.7. Commercial Restraints of the Companion Diagnostics Market
  • 9.8. Concluding Remarks

List of Tables

  • Table 2.1: Differences Between Traditional & Personalised Medicine, 2016
  • Table 2.2: Technologies and Platforms for Biomarker Research, 2016
  • Table 2.3: Examples of Clinically Relevant Cancer Biomarkers, 2016
  • Table 3.1: The World IVD Market: Main Segment Revenue Shares ($bn), 2015
  • Table 3.2: The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2020
  • Table 3.3: The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
  • Table 3.4: CDx Market Share (%) in the IVD Market, 2014, 2020, 2026
  • Table 4.1: Abbott Laboratories: Company Overview, 2016
  • Table 4.2: Abbott Laboratories: Historical Revenue ($bn), 2012-2015
  • Table 4.3: Abbott Laboratories: Biomarkers Pipeline, 2016
  • Table 4.4: Myriad Genetics: Company Overview, 2016
  • Table 4.5: Genomic Health: Company Overview, 2016
  • Table 4.6: Thermo Fisher Scientific: Revenue Sales ($bn), by Business Sector, 2012-2015
  • Table 4.7: Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2013-2015
  • Table 4.8: Johnson & Johnson: Revenues ($bn) and Shares (%) by Sector, 2015
  • Table 4.9: Johnson & Johnson: Revenues ($bn) by Sector, 2015
  • Table 4.10: Johnson & Johnson: Revenue ($bn) and Shares (%) by Region, 2015
  • Table 4.11: LabCorp: Revenues ($bn) and Shares (%) by Business Segment, 2015
  • Table 4.12: Selected List of LabCorp's Portfolio of Companion Diagnostics, 2016
  • Table 4.13: Selected List of LabCorp's Portfolio of Companion Diagnostics, 2016
  • Table 5.1: Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014
  • Table 5.2: Roche Diagnostics: Major Companion Diagnostic Projects, 2015
  • Table 5.3: Roche Diagnostics: List of Marketed Companion Diagnostics, 2015
  • Table 5.4: Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2010-2015
  • Table 5.5: Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2012-2015
  • Table 5.6: Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015
  • Table 5.7: bioMérieux: Revenue ($bn) and AGR (%), 2010-2015
  • Table 5.8: bioMérieux: Revenue ($bn) and Revenue Change (%) by Region, 2014-2015
  • Table 5.9: bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2014-2015
  • Table 5.10: Siemens Diagnostics: Ranking (#) by Sector, 2016
  • Table 5.11: MDxHealth: Companion Diagnostics Pipeline, 2016
  • Table 6.1: Other Leading Companion Diagnostics Partnerships, 2016
  • Table 6.2: List of Other Companies in the Companion Diagnostics Market, 2016
  • Table 6.3: List of Other Companies in the Companion Diagnostics Market, 2016

List of Figures

  • Figure 1.1: Companion Diagnostics Market Segmentation, 2016
  • Figure 2.1: The Pillars of Personalised Medicine
  • Figure 2.2: Type of Companion Diagnostics on the Basis of Application, 2016
  • Figure 3.1: The World IVD Market: Main Segment Revenue Shares (%), 2015
  • Figure 3.2: The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2015-2026
  • Figure 3.3: The World CDx Market Share (%) in the IVD Market, 2020
  • Figure 3.4: The World CDx Market Share (%) in the IVD Market, 2026
  • Figure 4.1: Thermo Fisher Scientific: Revenue Sales ($bn), by Business Sector, 2015
  • Figure 4.2: Thermo Fisher Scientific: Revenue Share (%) by Geography, 2015
  • Figure 4.3: Johnson & Johnson: Revenues ($bn) by Sector, 2015
  • Figure 4.4: Johnson & Johnson: Revenue Shares (%) by Sector, 2015
  • Figure 4.5: Johnson & Johnson: Revenue Shares (%) by Region, 2015
  • Figure 4.6: Johnson & Johnson: Revenue Share (%) for US, 2015
  • Figure 4.7: LabCorp: Revenues ($bn) by Business Segment, 2015
  • Figure 4.8: LabCorp: Revenue Shares (%) by Business Segment, 2015
  • Figure 5.1: Roche Diagnostics: Revenue ($bn) by Business Area, 2014
  • Figure 5.2: Roche Diagnostics: Revenue (%) by Business Area, 2014
  • Figure 5.3: Roche Diagnostics: Revenue (%) by Geography, 2014
  • Figure 5.4: Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2015
  • Figure 5.5: Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015
  • Figure 5.6: bioMérieux: Revenue ($bn) by Region, 2015
  • Figure 5.7: bioMérieux: Revenue Share (%) by Technology, 2015
  • Figure 8.1: Drivers and Restraints in the Companion Diagnostics Market, 2016-2026

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Alere
  • ARCA Biopharma
  • ARGENE
  • AstraZeneca
  • Bayer
  • Beckman Coulter
  • BioMarin Pharmaceutical
  • bioMérieux
  • Biocartis
  • Biomonitor
  • Boehringer Ingelheim
  • Brain Resource Company
  • Bristol-Myers Squibb
  • CancerGuide Diagnostics
  • Caprion Proteomics
  • Caris Life Sciences
  • Celldex Therapeutics
  • Cellestis
  • Cephalon
  • Cepheid
  • Clearstone Central Laboratories
  • Clinical Reference Laboratory
  • CompanDX
  • Compendia Bioscience
  • Crescendo Bioscience
  • Curidium Medica
  • Dako
  • DiagnoCure
  • DxS
  • Eli Lilly
  • Endocyte
  • Epitomics
  • Exosome Diagnostics
  • Explera
  • Flagship Biosciences
  • Foundation Medicine
  • Genfit
  • GenMark Diagnostics
  • Genomic Health
  • Genzyme Genetics
  • GlaxoSmithKline
  • HistologiX
  • Hologic
  • Ibis Biosciences
  • InDex Pharmaceuticals
  • Invivoscribe Technologies
  • Ipsen
  • Ipsogen
  • Johnson & Johnson
  • Knome
  • Lab21
  • LabCorp
  • Laboratory for Personalized Molecular Medicine
  • Life Technologies
  • MDxHealth
  • Medco Health Sciences
  • MedGenome
  • Merck
  • MolecularMD
  • Monogram Biosciences
  • Myriad Genetics
  • Nanosphere
  • Navigenics
  • Oncomed
  • Opko Health
  • Oxford BioTherapeutics
  • Pfizer
  • PharmaMar
  • Progenika Biopharma
  • Prometheus
  • QIAGEN
  • Quest Diagnostics
  • Quintiles Transnational Corporation
  • Randox Pharma Services
  • RiboMed Biotechnologies
  • Roche
  • SABioscience Corporation
  • Saladax Biomedical
  • Siemens
  • Signal Genetics
  • Sirius Genomics
  • Skyline Diagnostics
  • STARLIMS Technologies
  • SterilMed
  • Synthes
  • Takeda
  • Target Discovery
  • TcLand Expression
  • Theranostics (NZ)
  • Theranostics Health
  • TIB MolBiol
  • Tocagen
  • Tragara Pharmaceuticals
  • Transgene
  • Transgenomic
  • TrimGen Corporation
  • Unilabs
Back to Top